Marshall Wace’s Cardiff Oncology CRDF Stock Holding History

Marshall Wace’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$211K	Buy	+162,214	New	+$258K	﹤0.01%	2822
2025 Q3	–	Sell	-298,715	Closed	-$941K	–	2961
2025 Q2	$941K	Sell	298,715 -105,595	-26%	-$322K	﹤0.01%	1882
2025 Q1	$1.27M	Buy	404,310 +341,710	+546%	+$1.35M	﹤0.01%	1681
2024 Q4	$272K	Sell	62,600 -80,426	-56%	-$251K	﹤0.01%	2264
2024 Q3	$382K	Sell	143,026 -155,803	-52%	-$368K	﹤0.01%	2029
2024 Q2	$663K	Sell	298,829 -135,753	-31%	-$512K	﹤0.01%	1855
2024 Q1	$2.32M	Buy	+434,582	New	+$1.15M	﹤0.01%	1293
2022 Q1	–	Sell	-66,876	Closed	-$402K	–	3443
2021 Q4	$402K	Buy	66,876 +48,107	+256%	+$287K	﹤0.01%	2911
2021 Q3	$125K	Sell	18,769 -236,160	-93%	-$1.48M	﹤0.01%	2861
2021 Q2	$1.7M	Buy	+254,929	New	+$2.16M	0.01%	1516

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Marshall Wace's CRDF Position: Q2 2026 in Review

Marshall Wace opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 162,214 shares worth $211K. The stake represents ﹤0.01% of the portfolio and ranks #2822 among its holdings. This is a return to the name: Marshall Wace previously reported a position in CRDF as recently as Q2 2025.

Marshall Wace first reported a position in CRDF in Q2 2021 and has held it in 10 quarters since. The position peaked at $2.32M in Q1 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Marshall Wace held 162,214 shares of Cardiff Oncology worth $211K as of Q2 2026.
Cardiff Oncology was a new Marshall Wace position in Q2 2026.
Cardiff Oncology made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2822 holding.
Marshall Wace first reported a position in Cardiff Oncology in Q2 2021 and has held it in 10 quarters since.
Marshall Wace's Cardiff Oncology position peaked at $2.32M in Q1 2024.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.